Spark Therapeutics enters into licensing agreement with Genethon
Spark Therapeutics announced a licensing agreement with Genethon, a non-profit R&D organization dedicated to development of gene therapies for orphan genetic diseases, for development and commercialization of an AAV gene therapy targeting the liver to address a rare genetic disease. September 20, 2017